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Abstract
Background: Evidence is accumulating that a preclinical phase is present before the onset of clinical signs and
symptoms of rheumatoid arthritis (RA). This phase represents an important therapeutic window within which
interventions can dramatically modulate outcomes. An agent able to prevent RA for high risk individuals in this
phase is therefore desired. In this study, we investigated whether tryptophan metabolite, 5-hydroxytryptophan
(5-HTP) or 5-methoxytryptophan (5-MTP), can act as such an agent for primary prevention of collagen-induced
arthritis (CIA).
Methods: Mouse splenocytes were pretreated with 5-HTP or 5-MTP and activated by anti-CD3 plus anti-CD28
antibodies in vitro. The percentages of interferon-γ (IFNγ)+CD4+ T cells and interleukin-17 (IL-17)+CD4+ T cells were
measured by flow cytometry. The production of pro-inflammatory cytokines, serotonin and kynurenine was
measured by enzyme-linked immunosorbent assay. A CIA model was used to investigate the in vivo effects of
5-HTP on the prevention of arthritis.
Results: 5-HTP decreased the percentages of IFNγ+CD4+ T cells and IL-17+CD4+ T cells and suppressed the production
of IL-2, IL-4, IL-6, IL-17, tumor necrosis factor-α (TNFα) and IFNγ in activated splenocytes. 5-HTP administered before
induction decreased the disease activities in CIA mice and suppressed the production of TNFα, IL-6 and
cyclooxygenase-2 in arthritic joints. 5-HTP also increased serotonin, but decreased kynurenine in the CIA mice.
Conclusions: 5-HTP suppresses inflammation and arthritis through decreasing the production of pro-inflammatory
mediators. 5-HTP supplement before induction ameliorates arthritis in a CIA model.
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Background
Rheumatoid arthritis (RA) is a debilitating disease result-
ing in joint inflammation and deformity, leading to loss
of daily functions. With the advent of biologic agents,
clinical remission is achievable for many patients [1]. A
new frontier in the research into RA is at the earliest
stages of the disease. Discovery of circulating autoanti-
bodies, specifically anti-citrullinated protein antibodies
(ACPA), which are present years before clinical symp-
toms appear, helps to predict the chance of developing
RA in the future [2–6]. Evidence is accumulating that a
preclinical phase is present before onset of clinical signs
and symptoms, and this phase represents an important
therapeutic window within which interventions can dra-
matically modulate outcomes [2–6].
In addition to ACPA, smoking, genetic factors (HLA-
DRB1 shared epitope), and family history also play a role
in determining which individuals will ultimately develop
arthritis [2]. Individuals at risk should stop smoking. How-
ever, we lack agents which can effectively reduce their risk.
Because there are no symptoms or signs, an ideal agent
for the primary prevention would entail efficacy, low cost
and minimal side effects.
5-hydroxytryptophan (5-HTP) is an intermediate in
serotonin synthesis. It can easily cross the blood–brain
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barrier and increase the serotonin levels in the central
nervous system. Early studies found that 5-HTP mono-
therapy or 5-HTP used with other antidepressants can
improve mood and depression. In certain countries, 5-
HTP is used as a dietary supplement to treat depression,
suppress appetite, and ameliorate insomnia [7, 8]. Re-
cently, several studies found that 5-HTP is a potent me-
diator against inflammation. 5-HTP was found to
suppress the activation of p38 and nuclear factor-κB
(NF-κB) in fibroblasts [9], and decrease the expression
of interleukin (IL)-17 in peripheral blood mononuclear
cells (PBMCs) [10]. Moreover, 5-HTP suppresses the
production of tumor necrosis factor-α (TNFα) in lipopoly-
saccharide (LPS)-treated mice [11] and improves allergic
lung inflammation in a murine asthma model [12]. In
addition, 5-HTP and its metabolite 5-methoxytryptophan
(5-MTP) decreases the expression of cyclooxygenase-2
(COX-2) in A549 cells and suppresses cancer growth and
metastasis in mice [13]. These findings prompted us to
test whether 5-HTP can be an option for prevention or
treatment of collagen-induced arthritis (CIA), an animal
model for human RA.
We found that 5-HTP suppressed T cell activation and
pro-inflammatory cytokine production in activated sple-
nocytes. 5-HTP given before induction decreased the
disease activities in CIA mice. Furthermore, 5-HTP in-
creased the serotonin levels, but decreased the kynurenine
levels in the CIA mice. These findings suggest that 5-HTP
is a good agent for the prevention of CIA. Further studies
are warranted to investigate whether 5-HTP prevents RA
in healthy high-risk individuals in the preclinical phase.
Methods
Induction of CIA
DBA/1 mice were purchased from the Jackson Labora-
tory (Bar Harbor, ME, USA), and used at age 12–16
weeks under a protocol approved by the Institutional
Animal Care and Use Committee at the Changhua
Christian Hospital. For the induction of CIA, bovine
type II collagen (2 mg/ml in 0.05 M acetic acid) was
emulsified in complete Freund’s adjuvant (CFA) (con-
taining 5 mg/ml of killed Mycobacterium tuberculosis
H37Ra) at 4 °C for 12 hours. DBA/1 mice were injected
intradermally at the base of the tail with 100 μg collagen
in adjuvant at day 0, and boosted with an intraperitoneal
(i.p.) injection of 100 μg collagen at day 21. The arthritis
scores were monitored every other day following the
booster immunization. Collagen and adjuvant were pur-
chased from Chondrex, Inc. (Redmond, WA, USA).
CIA symptoms were evaluated visually in each limb
and graded on a scale of 0–4 as follows: grade 0, no ery-
thema or swelling; grade 1, erythema and swelling of the
ankle joint; grade 2, mild erythema and mild swelling in-
volving the entire paw; grade 3, moderate erythema and
moderate swelling involving the entire paw; and grade 4,
severe erythema and severe swelling involving the entire
paw. The CIA score for each mouse was the sum of the
scores for all four limbs (maximum score 16) [14].
Histology scores for ankle joints
Ankle joints were fixed in 10 % paraformaldehyde. Fol-
lowing decalcification (Shandon TBD-2 decalcifier,
Thermo Scientific, Waltham, MA, USA), dehydration
and paraffin-embedding, ankle tissues were cut into 6-
μm sections and stained with hematoxylin and eosin.
The levels of synovial hyperplasia, cartilage erosion, and
leukocyte infiltration were evaluated and scored separ-
ately on a scale of 0–2 points for each item (grade 0,
normal; grade 1, mild; and grade 2, severe) [15].
Administration of 5-HTP
The protocol is shown in Fig. 3a. Each group contained
eight mice. DBA/1 mice were divided into six groups:
group 1, treated with normal saline; groups 2 and 3:
treated with 5-HTP (Sigma-Aldrich, St. Louis, MO,
USA) at 32 and 160 mg/L, respectively, in drinking
water, from day 7 before induction to day 35; groups 4
and 5: treated with 5-HTP at 32 and 160 mg/L, respect-
ively, in drinking water, from day 20 to day 35; group 6,
treated with 5-HTP at 4 mg/kg through i.p. injection
every 3 days from day 7 before induction to day 35. The
study was done twice with similar results.
Immunohistochemistry (IHC) analysis of ankle joints
Ankle sections were processed through deparaffinization, re-
hydration and antigen retrieval, then incubated with rabbit
anti-TNFα polyclonal antibodies (Abs) (Bioss, Woburn, MA,
USA), anti-COX-2 Abs (clone: SP21, Thermo Scientific) or
rabbit anti-IL-6 polyclonal Abs (Abcam, Cambridge, MA,
USA) for 12 hours at 4 °C. Following incubation with goat
anti-rabbit IgG detection system (GBI Labs., Mukilteo,
WA, USA), 3,3-diaminobenzidine (DAB) Quanto sub-
strate (Lab Vision Co., Freemont, CA, USA) was used for
color development. Hematoxylin was used for counter-
staining. The expression of cyclooxygenase-2 (COX-2),
TNFα and IL-6 in the areas with mononuclear cell infiltra-
tion (positive area) were measured using a digital camera
and Image-Pro Plus 6.0 software.
Quantitative real-time polymerase chain reaction (PCR)
for mRNA levels of pro-inflammatory proteins
Formalin-fixed, paraffin-embedded ankle joint sections
were deparaffinized, rehydrated for 30 minutes at 37 °C,
then digested by proteinase K (60 mg/ml, Amresco Inc.,
Solon, Ohio, USA) at 60 °C. Total RNA was extracted using
a Quick-RNA™ MiniPrep kit (Zymo Research, Inc., Irvine,
CA, USA), and complementary DNA (cDNA) was synthe-
sized using a PrimeScript™ RT reagent kit (Takara Bio Inc.,
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Kyoto, Japan). The SYBR Green-based real-time PCR tech-
nique (KAPA Biosystems Inc., Wilmington, MA, USA) was
used to detect the messenger RNA (mRNA) levels of COX-
2, TNFα, IL-6, interferon-γ (IFNγ), IL-22 and NF-κB (p65).
The reaction was conducted with SYBG FAST qPCR mas-
ter mix for 40 cycles at 60 °C on the ABI 7300 real-time
PCR system (Applied Biosystems, Foster City, CA, USA).
No template control was used for exclusion of contamin-
ation in the assay. The threshold cycle of each gene was
normalized by β-actin expression and the final difference
for each group was presented as n-fold changes over the
control group.
In other experiments, splenocytes were treated with 5-
HTP and stimulated with anti-CD3 (0.5 μg/ml) plus
anti-CD28 (0.25 μg/ml) Abs for 12 hours. Antibodies
were purchased from BD Biosciences (San Diego, CA,
USA). Following total RNA isolation and cDNA synthe-
sis, SYBR Green-based real-time PCR and the ABI 7300
real-time PCR system were used to detect the mRNA
levels of COX-2, TNFα, IFNγ, IL-17, T-bet and RORγt.
Analysis of IFNγ+CD4+ T cells and IL-17+CD4+ T cells
Splenocytes from DBA/1 mice were treated with 5-HTP
or 5-MTP (Sigma-Aldrich) and stimulated with anti-CD3
plus anti-CD28 Abs for 36 hours. Protein transport inhibi-
tors were added in the last 4 hours. Following fixation and
permeabilization, splenocytes were incubated with
fluorescein isothiocyanate (FITC)-conjugated anti-CD3
Abs (clone: 145-2C11), PE-Cy5-conjugated anti-CD4
Abs (clone: RM4-5) and phycoerythrin (PE)-conjugated
anti-IFN-γ Abs (clone: XMG1.2) for 15 minutes. Stand-
ard 5-color flow cytometry (Beckman Coulter, FC-500)
was used to measure the percentage of IFNγ+CD4+ T
cells (IFNγ+CD3+CD4+/CD3+CD4+ cells).
For analysis of IL-17+CD4+ T cells, splenocytes treated
with 5-HTP or 5-MTP were incubated with IL-6 (20 ng/ml),
transforming growth factor-β (1 ng/ml), IL-23 (5 ng/ml),
anti-mouse IL-4 Abs (1 μg/ml), anti-mouse IFN-γ Abs
(1 μg/ml), anti-CD3 Abs and anti-CD28 Abs for 48
hours. Protein transport inhibitors were added in the
last 4 hours. Following fixation and permeabilization,
splenocytes were incubated with FITC-conjugated anti-
CD3 Abs (clone: 145-2C11), PE-Cy5-conjugated anti-
mouse CD4 Abs (clone: RM4-5) and PE-conjugated anti-
mouse IL-17 Abs (clone: TC11-18H10) for 15 minutes.
Flow cytometry was used to analyze the percentage of IL-
17+CD4+ T cells (IL-17+CD3+CD4+/CD3+CD4+ cells).
The antibodies were purchased from BD Biosciences, and
recombinant proteins were purchased from Biolegend
(San Diego, CA, USA).
In other experiments, splenocytes and lymph node
cells from the CIA mice at day 36 post-immunization
were stimulated with phorbol 12-myristate 13-acetate
(PMA, 50 ng/ml, Calbiochem, San Diego, CA, USA) and
ionomycin (500 ng/ml, Calbiochem) for 8 hours. Protein
transport inhibitors (BD Biosciences) were added in the
last 4 hours. Following fixation and permeabilization
(BD Cytofix/Cytoperm™ kit), these cells were incubated
with FITC-conjugated anti-CD3 Abs (clone: 145-2C11),
PE-Cy5-conjugated anti-CD4 Abs (clone: RM4-5) and
PE-conjugated anti-IFN-γ Abs (clone: XMG1.2) for 15
minutes. Antibodies were purchased from BD Biosci-
ences. Flow cytometry was used to measure the percent-
age of IFNγ+CD4+ T cells.
Analysis of cytokines
Serum samples were collected from CIA mice at day
36 post-immunization and the concentrations of IL-6,
IL-17, TNFα and IFNγ were measured by cytometric
bead array kits (BD Biosciences). In other experi-
ments, splenocytes from DBA/1 mice were treated
with 5-HTP in the presence of kynurenine (20 μg/ml,
Sigma-Aldrich), fluoxetine (5 μg/ml, Sigma-Aldrich)
or NSD-1015 (8.4 μg/ml, Sigma-Aldrich) and stimu-
lated with anti-CD3 plus anti-CD28 Abs for 36 hours.
The levels of TNFα (eBioscience, San Diego, CA,
USA), IL-17 (R&D Systems, Minneapolis, MN, USA),
IFNγ (eBioscience) and IL-2 (eBioscience) in the cul-
ture supernatants were measured by enzyme-linked
immunosorbent assay (ELISA).
Analysis of cell proliferation
Splenocytes from DBA/1 mice were treated with 5-HTP
and stimulated with anti-CD3 plus anti-CD28 Abs for
18 or 36 hours. WST-1 (Clontech, Mountain View, CA,
USA) was added in the last 2 hours and the absorbance
was measured at 450 nm (reference wavelength 690 nm)
by a Multiskan™ spectrophotometer (Thermo).
Analysis of cell death
Splenocytes from DBA/1 mice were treated with 5-
HTP and stimulated with anti-CD3 plus anti-CD28
Abs for 36 hours. The cells were incubated with 7-
aminoactinomycin D (7-AAD) and FITC-conjugated
annexin-V for 15 minutes. The percentage of cell
death (7-AAD+Annexin-V+ cells/total cells) was mea-
sured by flow cytometry. All reagents were purchased
from BD Biosciences. In other experiments, 5-HTP-
treated splenocytes were processed through fixation
and permeabilization, incubated with FITC-conjugated
anti-active caspase-3 Abs (clone: C92-605, BD Biosci-
ences) and PE-Cy5-conjugated anti-CD4 Abs (clone:
RM4-5) for 15 minutes. Flow cytometry was used to
measure the percentage of caspase-3+CD4+ cells
(caspase-3+CD4+/CD4+ cells).
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Analysis of serotonin and kynurenine
Serum samples were collected from CIA mice in group 1,
3 and 6 of the two independent animal studies at day 36
post-immunization and the levels of serotonin and kynur-
enine were measured using a serotonin ELISA (Enzo Life
Sciences Inc, Ann Arbor, MI, USA) and a KYN ELISA
(Cusabio Biotech Co., Ltd., Wuhan Hubei, China).
Analysis of PGE2 production
Serum samples were collected from CIA mice at day 36
post-immunization and the concentrations of prosta-
glandin E2 (PGE2) were measured by ELISA (Enzo). In
other experiments, splenocytes from DBA/1 mice were
treated with 5-HTP and stimulated with anti-CD3 plus
anti-CD28 Abs for 36 hours. The levels of PGE2 in the
culture supernatants were measured by ELISA.
Western blotting
5-HTP-treated splenocytes were incubated with radioim-
munoprecipitation assay (RIPA) lysis buffer (Millipore,
Temecula, CA, USA) for 30 minutes. Whole cell lysates
were quantified using a Bicinchoninic Acid Kit for pro-
tein determination (Sigma-Aldrich). The protein levels
of COX-2 (Abcam), PGE2 receptor EP2 (Abcam), T-bet
(Millipore) and RORγt (BD biosciences) were analyzed
by western blotting and quantified by Kodak Image 1D
software.
Statistics
Statistical analysis was performed using SPSS v12.0 soft-
ware. Multiple comparisons were performed using the
Kruskal-Wallis test, if significant (p <0.05), then the
Duncan test was used to find out which pairs were dif-
ferent. Spearman’s rank correlation was used to analyze
the correlation between the levels of serotonin, kynure-
nine and arthritis scores. In addition, the Mann–Whitney
test was used to analyze the effects of kynurenine, fluoxet-
ine and NSD-1015 on the cytokine production in 5-HTP-
treated splenocytes.
Results
5-HTP inhibited cell proliferation and cytokine production
in activated splenocytes
First, we analyzed the toxicity of 5-HTP to activated spleno-
cytes and found that treatment of 5-HTP at a level no more
than 50 μg/ml did not increase the levels of cell death, as
compared with cells without 5-HTP treatment (Fig. 1a, b).
Next, we studied the effects of 5-HTP on the activation
of splenocytes. The absorbance (optical density (OD)450–
OD690) in WST-1 treated cells is an index of cell prolifera-
tion [16]. The cell activity in activated splenocytes was de-
creased with 5-HTP at 10, 20 or 50 μg/ml (Fig. 1c). At
these levels, 5-HTP decreased the percentages of
IFNγ+CD4+ T cells and IL-17+CD4+ T cells in activated
splenocytes (Fig. 1d), and significantly decreased the levels
of mRNA and protein for IFNγ, TNFα and IL-17 (Fig. 1e, f).
In contrast, IL-2 production was decreased only at a
level of 50 μg/ml. Furthermore, 5-HTP decreased the
mRNA levels of T-bet, but did not inhibit RORγt ex-
pression (Fig. 2a). These findings suggest that 5-HTP
regulates cell proliferation and inhibits production of
pro-inflammatory cytokines in activated splenocytes.
We also studied the effects of 5-MTP, a metabolite of 5-
HTP, on the activation of splenocytes and found that 5-
MTP given at 10, 20 or 50 μg/ml did not affect the percent-
ages of IFNγ+CD4+ T cells or IL-17+CD4+ T cells (Fig. 1g).
Supplement of 5-HTP before induction decreased disease
activities in CIA mice
We investigated the effects of 5-HTP on the develop-
ment of CIA. The protocol for CIA induction and 5-
HTP supplementation is presented in Fig. 3a. 5-HTP did
not affect the body weight of these mice. We did not ob-
serve any side effects in mice receiving oral 5-HTP
(groups 1–5); however, parenteral 5-HTP induced a bout of
mild diarrhea within 30 minutes after injection (group 6).
The average consumption of water in each mouse was 5 ml
per day, thus the daily consumption of 5-HTP was equiva-
lent to 384 mg (groups 2 and 4) and 1,920 mg (groups 3
and 5) for a 60-kg person.
We found that the arthritis scores in group 3 and group
6 were significantly lower than those in group 1 (Fig. 3b).
Histology scores were also decreased in group 3 and
group 6 (Fig. 3c, d). These results suggest that 5-HTP
given before induction reduces CIA activity.
5-HTP decreased the production of TNFα and IL-6 in
arthritic joints
We investigated whether 5-HTP suppresses arthritis
through decreasing the production of pro-inflammatory cy-
tokines in arthritic joints. As shown in Fig. 4a, CIA mice
pretreated with 5-HTP (groups 3 and 6) had lower mRNA
levels of IFNγ and NF-κB (p65) compared with control
mice (group 1). 5-HTP also decreased the mRNA levels of
TNFα, IL-6 and IL-22; however, the differences were not
statistically significant (Fig. 4a). Furthermore, immunohisto-
chemistry analysis showed that 5-HTP decreased the pro-
duction of TNFα and IL-6 in the arthritic ankles (Fig. 4b).
We next studied the levels of cytokines in the serum
and found that 5-HTP did not affect the levels of IL-6,
TNFα, IFNγ and IL-17 (Fig. 3e). In addition, 5-HTP de-
creased the percentage of IFNγ+CD4+ T cells in the
inguinal lymph nodes, but not in the spleen (Fig. 3f ).
5-HTP decreased the production of COX-2 and PGE2 in
activated splenocytes and in CIA mice
5-HTP suppressed the expression of COX-2 and PGE2 re-
ceptor EP2 in activated splenocytes and reduced the PGE2
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levels in culture supernatants (Fig. 5a–c). In CIA mice, 5-
HTP also decreased the serum levels of PGE2 (Fig. 5d) and
suppressed the expression of COX-2 in inflamed ankle
joints (Fig. 4).
5-HTP given orally increased serotonin but decreased
kynurenine in the serum of CIA mice
To analyze the effects of 5-HTP supplement on trypto-
phan metabolism in CIA mice, serum levels of serotonin
Fig. 1 Effects of 5-hydroxytryptophan (5-HTP) on the activation of splenocytes. Splenocytes were treated with 5-HTP and stimulated with anti-CD3 plus
anti-CD28 Abs. a Percentages of annexin V+ 7-aminoactinomycin D (7-AAD)+ cells (annexin V+ 7-AAD+ cells/total cells, mean ± SD). b Percentages of
active caspase-3+CD4+ cells (active caspase-3+CD4+ cells/CD4+ cells, mean ± SD). c, WST-1 assay. Cell proliferation (mean ± SD) was defined as optical
density (OD)450–OD690. (–): cells without activation. d Percentages (mean ± SD) of IFNγ+CD4+ T cells (IFNγ+CD4+CD3+ cells/CD4+CD3+ cells) and IL-17
+CD4+ T cells (IL-17+CD4+CD3+ cells/CD4+CD3+ cells). e mRNA levels (mean ± SD) of IL-17, TNFα and IFNγ. f Protein levels (mean ± SD) of IL-2, IL-17,
TNFα and IFNγ in culture supernatant. g Percentages of IFNγ+CD4+ T cells and IL-17+CD4+ T cells (mean ± SD). *Significant compared with no 5-HTP
treatment. Multiple comparisons were performed using the Kruskal–Wallis test, if significant (p <0.05), then the Duncan test was used to find out which
pairs were different
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and kynurenine from CIA mice in groups 1, 3 and 6
were measured by ELISA. We found that CIA per se
markedly increased kynurenine levels in the mice (con-
trol group with no induction, 33.50 ± 9.10 ng/ml; group
1, 138.86 ± 15.71 ng/ml; mean ± SE); however, 5-HTP at-
tenuated this effect (group 3, 80.40 ± 12.41 ng/ml; group
6, 80.02 ± 10.92 ng/ml; mean ± SE) (Fig. 6a). In contrast,
CIA did not affect the serotonin levels in the mice (con-
trol group with no induction, 7.85 ± 0.76 ng/ml; group 1,
10.29 ± 1.28 ng/ml; mean ± SE); however, 5-HTP taken
orally significantly increased the serotonin level (group
3, 16.18 ± 1.34 ng/ml; mean ± SE) (Fig. 6a). In addition,
we analyzed the relationships between the serum levels
of tryptophan metabolites and disease activity, and found
that kynurenine levels were positively correlated with
arthritis scores (r = 0.38, p = 0.03) (Fig. 6b).
Tryptophan metabolites and inflammation
Certain selective serotonin re-uptake inhibitors (SSRIs)
can suppress the development of CIA in mice and de-
crease the production of pro-inflammatory cytokines in
human synovial membrane cells. In this study, we found
that fluoxetine suppressed the production of TNFα and
IFNγ in activated splenocytes. Moreover, fluoxetine and
5-HTP further decreased the production of the cytokines
(Fig. 6c). We also studied the effects of NSD-1015, an
inhibitor of aromatic amino acid decarboxylase on the
cytokine production and found that NSD-1015 increased
the production of TNFα and IFNγ in activated spleno-
cytes. NSD-1015 also restored the production of TNFα
and IFNγ inhibited by 5-HTP (Fig. 6c). In addition,
kynurenine decreased IFNγ production in activated
splenocytes. In contrast, kynurenine did not affect the
production of TNFα and IFNγ in 5-HTP-treated sple-
nocytes (Fig. 6c). These results suggest that there are
complicated interplays between tryptophan metabolites
and inflammation.
Discussion
Tryptophan is an essential amino acid for humans. It
has two major metabolic pathways: the serotonin
pathway and kynurenine pathway. In the serotonin
pathway, tryptophan is catalyzed into 5-HTP by tryp-
tophan hydroxylase-1 (TPH-1) and then converted
into serotonin. In the kynurenine pathway, tryptophan
is catalyzed into N-formylkynurenine by indoleamine
Fig. 2 Effects of 5-hydroxytryptophan (5-HTP) on the expression of T-bet and RORγt in activated splenocytes. Splenocytes were treated with 5-HTP and
stimulated with anti-CD3 plus anti-CD28 Abs. a mRNA levels (mean ± SD) of T-bet and RORγt. bWestern blotting for T-bet and RORγt. exp 1 and exp 2
experiment 1 and 2. *Significant compared with no 5-HTP treatment. Multiple comparisons were performed using the Kruskal–Wallis test, if significant
(p <0.05), then the Duncan test was used to find out which pairs were different
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2,3 dioxygenase (IDO) and then converts into kynure-
nine. 5-HTP suppresses inflammatory responses in
murine models of asthma and sepsis [11, 12]. 5-HTP
also inhibits the production of pro-inflammatory me-
diators in different cell lines [9, 10, 13]. These findings
made us interested in studying whether 5-HTP can
suppress inflammation and disease activity in CIA
mice.
We found that 5-HTP given at 10, 20 and 50 μg/ml
suppressed cell proliferation and decreased the produc-
tion of IFNγ+CD4+ T cells and IL-17+CD4+ T cells in ac-
tivated splenocytes. 5-HTP also suppressed the
expression of IL-17, TNFα, IFNγ and T-bet in activated
splenocytes. These findings did not result from cell
death, because we showed that 5-HTP did not increase
cell death at these levels.
Fig. 3 Effects of 5-hydroxytryptophan (5-HTP) on disease activity in the mice with collagen-induced arthritis (CIA). a Protocol for CIA induction and 5-HTP
supplement. CII bovine type II collagen, CFA complete Freund’s adjuvant. b and c Arthritis scores and histological scores (mean ± standard error (SE)).
d Histological staining of arthritic ankle joints. Ti tibia, Ta talus. e Serum cytokine levels (mean ± SE). f Percentages of IFNγ+CD4+ T cells (IFNγ+CD4+CD3+
cells/CD4+CD3+ cells, mean ± SE) in the spleen (Sp) and inguinal lymph nodes (Ln). *Significant compared with group 1. Each group contained eight mice.
Multiple comparisons were performed using the Kruskal–Wallis test, if significant (p <0.05), then the Duncan test was used to find out which pairs
were different
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In animal studies, a supplement of 5-HTP from
day 20 was not found to affect the disease course;
however, 5-HTP given from day 7 before induction
significantly decreased the arthritis scores and joint
inflammation. These results suggest that 5-HTP
supplement can be an option for prevention of
arthritis.
5-HTP taken orally was shown to suppress allergic lung
inflammation even though cytokine levels were not
decreased on bronchoalveolar lavage [12]. In the current
study, we also found that 5-HTP did not affect the
cytokine levels in the serum and the percentages of
IFNγ+CD4+ T cells in the spleen. However, 5-HTP sup-
pressed the expression of TNFα and IL-6 in the in-
flamed ankle joints and decreased the percentages of
IFNγ+CD4+ T cells in the draining lymph nodes. These
results suggest that 5-HTP decreased arthritis activity
without affecting systemic immunity.
Fig. 4 Effects of 5-hydroxytryptophan (5-HTP) on the expression of pro-inflammatory mediators in the arthritic joints. a mRNA levels (mean ±
standard error) of TNFα, IL-6, IFNγ, IL-22, cyclooxygenase-2 (COX-2) and NF-κB (p65) in the arthritic joints. b Immunohistochemistry staining for
TNFα, IL-6 and COX-2 in the arthritic ankles. The expressions of these proteins in the areas with mononuclear cell infiltration (positive area) were
measured using a digital camera and Image-Pro Plus 6.0 software (Media Cybernetics Inc., Bethesda, MD, USA). The grouping was as described in
Fig. 3a. At least four mice in each group were studied. *Significant compared with group 1. Multiple comparisons were performed using the Krus-
kal–Wallis test, if significant (p <0.05), then the Duncan test was used to find out which pairs were different
Yang et al. Arthritis Research & Therapy  (2015) 17:364 Page 8 of 12
Decreased levels of serotonin in the central nervous
system are associated with major depressive disorders.
Treatment with SSRIs or supplement of serotonin pre-
cursors is an important strategy in depression therapy.
SSRIs can block serotonin re-uptake and thus increase
serotonin levels in the brain and improve depression
[17–19]. Interestingly, certain SSRIs can decrease the
production of pro-inflammatory cytokines [20, 21], sup-
press airway inflammation in asthma patients [22], and
reduce disease activity in RA patients [23]. SSRIs have
also been found to decrease the arthritis scores in CIA
mice and suppress cytokines production in macrophages
and synovial membrane cells [24]. In this study, we
found that fluoxetine effectively decreased the produc-
tion of IFNγ and TNFα in activated splenocytes.
In our animal study we found that 5-HTP given orally
increased the serum levels of serotonin, whereas paren-
teral 5-HTP did not affect the serum levels of serotonin
in CIA mice. These results suggest that regulation of
the serotonin levels is unlikely the major mechanism
behind the suppression of arthritis by 5-HTP in the
CIA mice.
RA patients have increased kynurenine levels in the
blood [25–27] and the levels are positively correlated
with C-reactive protein [28, 29]. In addition, RA pa-
tients have increased IDO activity in the synovial fluid
Fig. 5 Effects of 5-hydroxytryptophan (5-HTP) on the expression of cyclooxygenase-2) (COX-2 and prostaglandin E2 (PGE2) in activated splenocytes
and mice with collagen-induced arthritis (CIA). a mRNA levels (mean ± SD) of COX-2 in activated splenocytes. b Protein levels of COX-2 and PGE2
receptor EP-2 in activated splenocytes. N.D. undetectable. exp 1 and exp 2 experiment 1 and 2. c and d PGE2 levels (mean ± standard error) in the
culture supernatants and mice serum. *Significant compared with no 5-HTP treatment cells (a and c) or group 1 (d). The grouping (d) was as
described in Fig. 3a. At least six mice in each group were studied (d). Multiple comparisons were performed using the Kruskal–Wallis test, if significant
(p <0.05), then the Duncan test was used to find out which pairs were different
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[26]. Interestingly, pro-inflammatory cytokines such as
TNFα, IL-1 and IFNγ can increase IDO expression and
promote serotonin re-uptake, resulting in increased
levels of kynurenine and decreased levels of serotonin
[7, 30–33]. Our study showed that mice with a higher
arthritis score were more likely to have high serum
levels of kynurenine (Fig. 6b). Most of these mice re-
ceived 5-HTP before or after immunization.
Fig. 6 Effects of 5-hydroxytryptophan (5-HTP) on the production of serotonin and kynurenine in the mice with collagen-induced arthritis (CIA).
Serum levels of serotonin and kynurenine in the CIA mice from groups 1, 3 and 6 were measured by ELISA. a Serum levels of serotonin and
kynurenine (mean ± standard error) in the CIA mice. *Significant compared with group 1. (–) same-aged DBA/1 mice. The grouping was as
described in Fig. 3a. Multiple comparisons were performed using the Kruskal–Wallis test, if significant (p <0.05), then the Duncan test was used
to find out which pairs were different. b Correlations between the levels of serotonin, kynurenine and arthritis scores in the CIA mice. Statistical
analysis was performed using Spearman’s rank correlation. c Splenocytes were treated with 5-HTP alone or in combination with kynurenine, fluoxetine
or NSD-1015, and then stimulated with anti-CD3 plus anti-CD28 Abs. Cytokine levels (mean ± SD) of TNFα and IFNγ in culture supernatants were
measured N.D. undetectable. a Significant compared with control group/column one. b Significant compared with 5-HTP (20 μg/ml). c Significant
compared with 5-HTP (50 μg/ml). The Mann–Whitney test was used to analyze the effects of kynurenine (Kynu), fluoxetine (Fluo) and NSD-1015 on
the cytokine production in 5-HTP-treated splenocytes
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5-HTP is indicated for depression, obesity, headaches,
fibromyalgia and insomnia. Administration of 5-HTP re-
sults in nausea, diarrhea, and vomiting in some patients;
nevertheless, these side effects are mild and there are no
significant laboratory abnormalities in these patients. In
short, 5-HTP supplement is well-tolerated and causes
minimal side effects. In clinical studies, the doses of 5-
HTP in the treatment of depression have been from 20
to 3,250 mg per day [7, 8, 34, 35]. Treatment with 5-
HTP at 600 mg per day was also found to decrease the
frequency of migraine and improve insomnia [8]. In a
murine model of asthma, the amount of 5-HTP given to
the mice was equivalent to consumption of 200 mg per
day by a 45-kg person [12]. In our animal study, 5-HTP
given orally did not affect body weight or cause diarrhea.
However, the daily consumption of 5-HTP was equiva-
lent to 384 mg and 1,920 mg per day by a 60-kg person,
respectively. Furthermore, 5-HTP given by i.p. injection
at 30, 100 and 300 mg/kg was found to decrease the
production of TNFα in a sepsis model [11]. Parenteral
5-HTP is known to increase intestinal peristalsis
resulting in diarrhea. In order to avoid severe diarrhea
and dehydration, we gave the mice 5-HTP by i.p. in-
jection at a much lower dose (4 mg/kg every 3 days).
Even though mild diarrhea still occurred after each in-
jection, it was well-tolerated. More importantly, these
mice had improved arthritis scores and decreased joint
inflammation.
Conclusions
This study provides in vitro and in vivo evidence that 5-
HTP, a tryptophan metabolite, can regulate immune
responses. 5-HTP supplement before induction can
decrease disease activity, suppress joint inflammation
and cause minimal side effects in CIA mice. Further
studies are required to elucidate whether 5-HTP, a com-
mon dietary supplement can act as an agent for primary
prevention of RA.
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